12-Nov-2024 3:00 PM CST - Business Wire Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy and a steady increase in demand, said Scott Braunstein, M.D., Chairman and Chief Executive Officer of
20-Sep-2024 7:00 AM CST - Business Wire Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY in TSC at Investor and Analyst Day Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Companys development program for ZTALMY (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024
12-Nov-2024 3:00 PM CST - Business Wire Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy and a steady increase in demand, said Scott Braunstein, M.D., Chairman and Chief Executive Officer of
20-Sep-2024 7:00 AM CST - Business Wire Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY in TSC at Investor and Analyst Day Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Companys development program for ZTALMY (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024
